Results 51 to 60 of about 25,328 (173)

Predictive Value of Nutrition Indices in Advanced Hepatocellular Carcinoma Patients Treated With Lenvatinib

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT The prognostic nutritional index (PNI) and geriatric nutritional risk index (GNRI) are simple markers that reflect immune and nutritional status. This retrospective study evaluated their prognostic significance in 276 patients with advanced hepatocellular carcinoma (HCC) who received first‐line lenvatinib. PNI and GNRI were calculated based on
Cheng‐Wei Kuo, Wei‐Chen Tai, Yen‐Hao Chen, Ming‐Chao Tsai, Jing‐Houng Wang, Sheng‐Nan Lu, Tsung‐Hui Hu, Chao‐Hung Hung, Chien‐Hung Chen, Yuan‐Hung Kuo   +9 more
wiley   +1 more source

Contemporary Treatment Patterns in Surgically Treated Temporal Bone Cancer

The Laryngoscope, EarlyView.
In a national cohort of 811 surgically treated temporal bone cancer patients, adjuvant radiation therapy was the most frequently utilized postoperative treatment (20.3%), while chemotherapy and immunotherapy were used far less frequently. Multimodal treatment, particularly combined parotidectomy and neck dissection, was strongly associated with higher ...
Raquel Rowell, Christopher Z. Wen, Vera Bzhilyanskaya, Jane Y. Tong, Adam C. Kaufman   +4 more
wiley   +1 more source

Interstitial Lung Disease in Patients With Unresectable Stage III NSCLC Treated With Chemoradiotherapy Followed by Durvalumab in Japan: Analysis From the Multicenter Prospective AYAME Study

Thoracic Cancer
Introduction Interstitial lung disease (ILD) is a concerning adverse event associated with immune checkpoint inhibitors, including durvalumab. This analysis of the multicenter AYAME study assessed the longterm safety of durvalumab, focusing on ILD ...
Nobuyuki Yamamoto, Hirotsugu Kenmotsu, Kiichiro Ninomiya, Burak Akdemir, Shinya Uematsu, Ayako Fukui, Ryo Koto, Masakazu Fujiwara, Chikako Iwao, Hiroshi Kitagawa, Ichiro Yoshino, Akihiko Gemma, Tetsuya Mitsudomi, Yoshinobu Saito   +13 more
doaj   +1 more source

Phimosis: A rare complication of immunotherapy with durvalumab

Urology Case Reports, 2020
We present a case of a 69 year old man with phimosis associated with immunotherapy with durvalumab for metastatic non-small-cell lung cancer. The patient developed vitiligo like dermatosis after the induction dose of durvalumab, subsequent administration
Luis Gabriel Vázquez-Lavista, Luis Llorente, Jorge Alatorre-Alexander, José Arturo Ramírez-Muciño   +3 more
doaj   +1 more source

Radiation‐free or Chemo‐free: Rethinking the Best Strategy for PD‐L1‐High, Unresectable Stage III NSCLC

Precision Radiation Oncology, EarlyView.
This article discusses the emerging radiotherapy‐free and chemo‐free strategies in PD‐L1–high, unresectable stage III NSCLC, reviewing the Evolution trial and comparing it with existing treatments. We highlight the need for further research to validate these approaches and ensure safe de‐escalation without compromising ...
Yongbo Xiang, Nan Bi
wiley   +1 more source

Rising incidence of radiation pneumonitis after adjuvant durvalumab in NSCLC patients treated with concurrent chemoradiotherapy

Acta Oncologica
Background and purpose: Adding adjuvant durvalumab to chemoradiotherapy (CRT) improves overall survival (OS) rates in locally advanced Non-Small-Cell Lung Cancer (NSCLC).
Rutger H. Stoffers, Anne G.H. Niezink, Olga Chouvalova, Jan F. Ubbels, Marleen Woltman-van Iersel, T. Jeroen N. Hiltermann, Lucie B.M. Hijmering-Kappelle, Gea Douma, Sander M. de Hosson, John W.G. van Putten, Friso T. Zandberg, Lisanne V. van Dijk, Johannes A. Langendijk, Robin Wijsman   +13 more
doaj   +1 more source

Design, synthesis and activity evaluation of tetrahydroisoquinoline‐based programmed cell death ligand 1 inhibitors

Smart Molecules, EarlyView.
Based on a 3D‐quantitative structure‐activity relationship pharmacophore model, structural optimization of Y6 yielded Y7f. Mechanistic studies revealed that Y7f acted as a programmed death receptor 1/programmed cell death ligand 1 (PD‐L1) interaction inhibitor by inducing PD‐L1 dimerization. Y7f restored T‐cell function.
Menglin Yu, Sen Cai, Yanyan Pan, Heshuang Wang, Fengwu Zhang, Aiyu Ma, Shixuan Lv, Xiuhan Guo, Shisheng Wang, Qiling Song, Chunyan Ma, Shuai Wang, Li Zhang, Jian Wang, Qingwei Meng, Yueqing Li   +15 more
wiley   +1 more source

Australian Practical Guide on the Management of Muscle‐Invasive Bladder Cancer

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Australia's management of muscle‐invasive bladder cancer is evolving, with increased use of perioperative therapy and emerging immunotherapies. However, challenges such as cisplatin ineligibility, limited access, and costs persist. Expanding bladder‐sparing approaches, precision medicine, and integrated care pathways will be key to improving outcomes ...
Dickon Hayne, Shomik Sengupta, Alison Y. Zhang, Niara Oliveira, Manish I. Patel, Ian Vela, Ian D. Davis   +6 more
wiley   +1 more source

Interstitial Lung Disease due to Tepotinib after Durvalumab in a Patient with Lung Adenocarcinoma Harbouring MET Exon 14 Skipping Mutation: A Case Report

Case Reports in Oncology
Introduction: Tepotinib is a targeted agent for patients with advanced non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutation (METex14).
Ryota Tatsuhige, Keiki Yokoo, Taku Hatakeyama, Takayuki Nagao, Satoshi Ota, Gen Yamada, Hirofumi Chiba   +6 more
doaj   +1 more source

Skin Abnormalities at Checkpoint Inhibitor Therapy Initiation Are Associated With Skin Rash Development in Oncology Patients

Allergy, EarlyView.
Skin tape strip lipidomic analysis revealed preexisting skin barrier lipid abnormalities at day 0 that were further exacerbated after 6 weeks of CPI treatment. Significant changes in skin (but not plasma) proinflammatory cytokines were identified in future ircAE patients after 6 weeks of CPI immunotherapy.
Taras Lyubchenko, Evgeny Berdyshev, Ryan M. Weight, Olivia Xiao, Neil J. Shah, Alina Markova, Mario E. Lacouture, Jeffrey A. Kern, Elena Goleva, Donald Y. M. Leung   +9 more
wiley   +1 more source